uniQure N.V. (QURE)
| Market Cap | 1.70B |
| Revenue (ttm) | 500.20M |
| Net Income (ttm) | 303.44M |
| Shares Out | 46.07M |
| EPS (ttm) | 6.65 |
| PE Ratio | 5.46 |
| Forward PE | 27.93 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 186,363 |
| Open | 35.74 |
| Previous Close | 36.81 |
| Day's Range | 34.82 - 36.34 |
| 52-Week Range | 25.80 - 52.19 |
| Beta | 1.21 |
| Analysts | Strong Buy |
| Price Target | 66.92 (+84.2%) |
| Est. Earnings Date | Oct 26, 2021 |
About QURE
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; ...
Financial Performance
In 2020, uniQure's revenue was $37.51 million, an increase of 415.23% compared to the previous year's $7.28 million. Losses were -$125.02 million, 0.66% more than in 2019.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for uniQure stock is "Strong Buy." The 12-month stock price forecast is 66.92, which is an increase of 84.20% from the latest price.
News
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal
The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others
This Simple Thing Sent These 3 Nasdaq Stocks Soaring Tuesday
All it takes is money -- big money.
uniQure to Participate in Multiple Upcoming Industry Conferences in September
LEXINGTON, Mass. and AMSTERDAM, Sept. 07, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...
uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Moni...
~ No Significant Safety Concerns Observed Across a Total of 14 Completed Procedures ~
UniQure (QURE) Q2 Earnings and Revenues Top Estimates
uniQure (QURE) delivered earnings and revenue surprises of 198.60% and 118.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
~ Expanded gene therapy pipeline with four new research programs and announced acquisition of Corlieve Therapeutics ~
UniQure (QURE) to Report Q2 Results: Wall Street Expects Earnings Growth
UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Late-Stage Clinical Study Readouts Biotech Investors Should Watch
Several drugmakers have important clinical trial updates on the way.
uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, July 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe...
What's Next For uniQure Stock After A 13% Drop Last Week?
The stock price of uniQure stock, a gene therapy company, has seen a a large 13% drop over the last five trading days. The company recently announced that the U.S. FDA has asked for eighteen months of d...
One Year Following Single Administration, UniQure's Hemophilia B Gene Therapy Candidate Shows Sustained Increase In F...
UniQure N.V. (NASDAQ: QURE) has announced 52-week data from its Phase 3 HOPE-B gene therapy trial of etranacogene dezaparvovec to treat hemophilia B.
UniQure Expands Gene Therapies Pipeline For Neurological Disorders With Corlieve Acquisition
UniQure N.V. (NASDAQ: QURE) has agreed to acquire Corlieve Therapeutics and its lead program for temporal lobe epilepsy (TLE), the most common form of focal epilepsy.
uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy ...
~ Sustained increases in Factor IX (FIX) levels with mean FIX activity of 41.5 percent of normal in full study population one year following a single administration of etranacogene dezaparvovec ~
uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)
~ Expands uniQure's Pipeline of Innovative Gene Therapies to Treat Neurological Disorders ~
uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the T...
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, June 16, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe...
Alliance Data, Cimarex Energy, Myriad Genetics, Nestle and More Tuesday Afternoon Analyst Research Calls
The markets were lower across the board on Tuesday afternoon. All eyes on Wall Street are focused on the two-day Federal Reserve meeting, which began Tuesday, as many are waiting to hear how the narrati...
UPDATE -- uniQure to Participate in Multiple Upcoming Industry Conferences in June
~ uniQure to host virtual Research & Development Day on June 22, 2021 ~ ~ uniQure to host virtual Research & Development Day on June 22, 2021 ~
uniQure to Participate in Multiple Upcoming Industry Conferences in June
~ uniQure to host virtual Research & Development Day on June 22, 2021 ~ ~ uniQure to host virtual Research & Development Day on June 22, 2021 ~
DSMB Recommends UniQure To Continue Huntington's Gene Therapy Trial Unchanged
The independent Data Safety Monitoring Board (DSMB) has reviewed safety data for the fully enrolled first cohort of ten patients of the Phase 1/2 trial evaluating UniQure NV's (NASDAQ: QURE) AMT-130 for...
uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntin...
Independent Data Safety Monitoring Board Recommends Proceeding with Second, Higher-Dose Cohort Independent Data Safety Monitoring Board Recommends Proceeding with Second, Higher-Dose Cohort
uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antib...
~ Data Show No Clinically Significant Correlation Between Pre-Existing NAbs and FIX Activity ~
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
uniQure (QURE) delivered earnings and revenue surprises of -2.25% and -89.98%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress
~ 52-week follow-up data from HOPE-B pivotal study expected to be presented later this quarter ~
Why Moderna, uniQure And Novavax Are Moving Today
Moderna, Inc. (NASDAQ: MRNA). uniQure N.V.
CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezapar...
KING OF PRUSSIA, Pa., May 6, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced the closing of its global Commercialization and License agreement with uniQure (NASDAQ: QURE) ...